



Curriculum Vitae Europass

Personal information

First name(s) /Surname(s) **Monica Piedimonte**

E-mail monica.piedimonte@uniroma1.it

Year of birth 1983

Occupational field **Hematology**

Work experience

Date	Position
2019 to present	Research fellow, Department of Clinical and Molecular Medicine, Sapienza University of Rome MD, UOC of Hematology, S. Andrea Hospital, Sapienza University of Rome
2017 to present	PhD Student in Hematology, Department of Molecular Medicine, Sapienza University of Rome
2017 to present	MD, "Casa di Cura di Nepi"
2012-2017	Resident in Hematology, UOC of Hematology, S. Andrea Hospital, Sapienza University of Rome
2009-2012	Training in Hematology, Policlinico Umberto I, Sapienza University of Rome
2010-2011	Training in Hematology, Cliniques Universitaires "Saint Luc", Bruxelles
2005	Visiting investigator, Laboratory of Immunology and Pathology, Department of Biology, University of Rome Tor Vergata

Education

Dates	2019-today
Title of qualification awarded	Research fellow, Department of Clinical and Molecular Medicine, Sapienza University of Rome
	2017-today
	PhD School in Immunological, Haematological and Rheumatological Sciences and Innovation in Immuno-mediated and hematological disorders, Department of Molecular Medicine, Sapienza University of Rome
	2012-2017
	Specialization in Hematology Sapienza, University of Rome
	2005-2011
	Degree of Medicine and Surgery Sapienza, University of Rome
	2002-2005
	Degree in Biotechnology Tor Vergata, University of Rome
	2002
	High school "Liceo Classico"

Mother tongue(s)

Italian

Other languages
Self-assessment
European level ()*

Understanding		Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production	
English	B2	B2	B2	B2	B2	B1	
French	B1	B1	B1	B1	B1	A2	

(*)Common European Framework of Reference for Languages

Other informations

Research projects:

- An integrated functional-transcriptomic approach to target novel pathways with small molecules in acute myeloblastic leukemia (grant Ateneo 2018).
- Metabolic analysis in Chronic Lymphocytic Leukemia (PhD Program).

Teaching activities:

- Tutor in Hematology for medical students of Sapienza University of Rome
- Master II Livello "Tecniche di ottimizzazione e contenimento del supporto trasfusionale in emocomponenti", Department of Clinical and Molecular Medicine, Sapienza University of Rome

Member of:

SIE, SIES, GITMO, SEIFEM, Società Italiana di Amiloidosi, FIL, RTN and Gruppo Laziale Malattie Rare.

Investigator in:

- 63935937MDS3001: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) treatment
- AG-221-AML-005 : A phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subject with Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who are not Candidates to Receive Intensive Induction Chemotherapy.
- EORTC-1301-LG: Confronto tra terapia con decitabina della durata di 10 giorni rispetto alla chemioterapia convenzionale ("3+7") seguita da trapianto allogenico in pazienti con AML > 60 anni: studio di fase III randomizzato del Leukemia Group di EORTC, CELG, GIMEMA e del gruppo di studio tedesco sulle SMD
- Evidence Study: Valutazione della persistenza al trattamento con Ibrutinib in pazienti affetti da Leucemia Linfocitica Cronica nella reale pratica clinica
- Robust-CC5013-DLC002 : A Phase 3 randomized, double-blind, placebo controlled, multicenter study to compare the efficacy and safety of Lenalidomide (CC-5013) plus R-CHOP Chemotherapy (R2-CHOP) versus placebo plus R-CHOP chemotherapy in subjects with previously untreated activated B-Cell type diffuse large B-Cell Lymphoma.
- Augment-CC5013-NHL007: A Phase 3, double-blind randomized study to compare the efficacy and safety of rituximab plus lenalidomide (CC-5013) versus Rituximab plus placebo in subjects with relapsed/refractory indolent Lymphoma.
- FIL DEVEC: A phase II study of metronomic chemotherapy in elderly non-fit patients (>65 years) with aggressive B-Cell Lymphomas"
- ACE-536-MDS-002: A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions
- M15-954: A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher Risk MDS)
- GIMEMA AML2120: A retrospective and prospective multicentre observational study for the evaluation of incidence of familial AML/MDSs in patients with myeloid neoplasms AML/MDS
- Studio Perla " Studio prospettico, osservazionale, di coorte su Lonquex (Lipegfilgrastim) utilizzato nella pratica clinica per il trattamento profilattico della neutropenia indotta da chemioterapia (CIN) in pazienti adulti con malattie ematologiche maligne sottoposti a chemioterapia (CT) mielosoppressiva.
- Studio multicentrico, non interventistico, prospettico per valutare l'incidenza di infezioni fungine invasive e per monitorare l'approccio diagnostico e terapeutico degli eventi febbrili di sospetta natura fungina in pazienti affetti da neoplasie ematologiche (Hema e-Chart II)
- Studio prospettico, aperto, randomizzato, multicentrico di confronto tra due approcci terapeutici per il trattamento delle infezioni fungine invasive nel paziente onco-ematologico neutropenico: trattamento empirico vs. approccio presuntivo ("pre-emptive"). Protocollo AIFA-FARM07PBW.
- Risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Protocollo Gimema AML1310.
- Prospective survey on severe infections during a multi center study of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Protocollo Gimema AML1411.
- Valutazione prospettica multicentrica dei livelli plasmatici di posaconazolo in pazienti affetti da malattie ematologiche in profilassi antifungina con posaconazolo (Studio POSA-TDM 2012)
- Valutazione prospettica dei livelli plasmatici di voriconazolo in pazienti affetti da malattie ematologiche in trattamento antifungino con voriconazolo (Studio VORI-TDM 2011).
- SIGNB-GITMO-AMCLI Survey Studio prospettico, multicentrico di sorveglianza delle gravi infezioni da batteri gram negativi in pazienti sottoposti a trapianto autologo ed allogenico di cellule staminali emopoietiche.
- GIMEMA EMATO 0213 Clinical Practice in the prophylaxis and treatment of arterial and venous thromboembolism in patients with hematological Neoplasms and Low Platelets (PENELOPE Observational Study)
- LAL1913: National Treatment Program for Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy

- Protocol PB-06-007: Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial (Protalix).
- MPD-Petit-01. Valutazione delle caratteristiche cliniche e biologiche, dei diversi trattamenti utilizzati e dell'andamento a lungo termine di bambini e adolescenti con trombocitemia e policitemia seguiti in un singolo centro. Sperimentatori: Prof. Robin Foà e Dr.ssa Fiorina Giona
- CML-Petit-01. Valutazione della risposta clinica, citogenetica, e molecolare all'Imatinib ad elevato dosaggio in bambini ed adolescenti con Leucemia Mieloide Cronica Philadelphia positiva in fase cronica, alla diagnosi o dopo resistenza/intolleranza. Sperimentatori: Prof. Robin Foà e Dr.ssa Fiorina Giona
- Qualità di vita nel bambino piastrinopenico (in collaborazione con l'Università degli Studi di Bari).
- Valutazione microscopica e con contaglobuli automatico delle dimensioni piastriniche per la diagnostica differenziale delle piastrinopenie isolate (in collaborazione con l'Università di Pavia)
- Effetti morfofunzionali a lungo termine della chemioterapia combinata ABVD e radioterapia sul sistema endocrino di soggetti affetti da Linfoma di Hodgkin in età pediatrica (in collaborazione col Dipartimento di Endocrinologia della Sapienza, Prof. A. Lenzi).

Publications

1. Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. Busca A, Cattaneo C, De Carolis E, Nadali G, Offidani M, Picardi M, Candoni A, Ceresoli E, Criscuolo M, Delia M, Della Pepa R, Del Principe I, Fanci RR, Farina F, Fracchiolla N, Giordano C, Malagola M, Marchesi F, Piedimonte M, Prezioso L, Quinto AM, Spolzino A, Tisi MC, Trastulli F, Treccarichi EM, Zappasodi P, Tumbarello M, Pagano L; SEIFEM (Sorveglianza Epidemiologica delle Infezioni nelle Emopatie). *Crit Rev Oncol Hematol*. 2021 Feb;158:103203.
2. Cattaneo C, Busca A, Gramegna D, Farina F, Candoni A, Piedimonte M, Fracchiolla N, Pagani C, Principe MID, Tisi MC, Offidani M, Fanci R, Ballanti S, Spolzino A, Criscuolo M, Marchesi F, Nadali G, Delia M, Picardi M, Sciumé M, Mancini V, Olivieri A, Tumbarello M, Rossi G, Pagano L. Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study. *Hemasphere*. 2019 Nov 4;3(6):e320.
3. Campagna A, Gianfelici V, Antolino G, Pelliccia S, Galassi G, Piedimonte M, Bianchi MP, Mirabilii S, Ricciardi MR, Tasca G, Iorio R, Conte E, Ferrari A, La Verde G, Tafuri A. Central nervous system immune reconstitution inflammatory syndrome after autologous stem cell transplantation. *Bone Marrow Transplant*. 2020 Jan;55(1):268-27
4. Del Principe MI, Dragonetti G, Verga L, Candoni A, Marchesi F, Cattaneo C, Delia M, Potenza L, Farina F, Ballanti S, Decembrino N, Castagnola C, Nadali G, Fanci R, Orciulo E, Veggia B, Offidani M, Melillo L, Manetta S, Tumbarello M, Venditti A, Busca A, Aversa F, Pagano L; Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group. 'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. *J Antimicrob Chemother*. 2019 Jan 14.
5. Piedimonte M, Ottone T, Alfonso V, Ferrari A, Conte E, Divona MD, Bianchi MP, Ricciardi MR, Mirabilii S, Licchetta R, Falco F, Campagna A, Cicconi L, Galassi G, Pelliccia S, Leporace A, Lo Coco F, Tafuri A. Rare BCR/ABL fusion proteins and their clinical significance into Ph+ Acute Myeloid Leukemias. *BMC Cancer*. 2019 Jan 10;19(1):50.
6. Candoni A, Klimko N, Busca A, De Blasi R, Shadrivova O, Cesaro S, Zannier ME, Verga L, Forghieri F, Calore E, Nadali G, Simonetti E, Muggeo P, Quinto AM, Castagnola C, Cellini M, Del Principe MI, Fracchiolla N, Melillo L, Piedimonte M, Zama D, Farina F, Giusti D, Mosna F, Capelli D, Delia M, Picardi M, Decembrino N, Perruccio K, Vallero S, Aversa F, Fanin R, Pagano L; SEIFEM Group (Epidemiological Surveillance of Infections in Hematological Diseases). Fungal infections of the central nervous system and paranasal sinuses in Onco-hematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases. *Mycoses*. 2018 Dec 19.
7. Tendas A, Marchesi F, Mengarelli A, Annibaldi O, Tomarchio V, Saltarelli D, Chierichini A, Di Venanzio M, Sollazzo F, Piedimonte M, Cupelli L, Bruno A, De Angelis G, Delbono L, Niscola P, Perrotti AP, de Fabritiis P, Arcese W; Rome Transplant Network. Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. *Support Care Cancer*. 2018 Dec 18.
8. Mirabilii S, Ricciardi MR, Piedimonte M, Gianfelici V, Bianchi MP, Tafuri A. Biological Aspects of mTOR in Leukemia. *Int J Mol Sci*. 2018 Aug 14;19(8).
9. Girmenia C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A, Cattaneo C, Raiola AM, Guidi S, Iori AP, Candoni A, Irrera G, Milone G, Marcacci G, Scimè R, Musso M, Cudillo L, Sica S, Castagna L, Corradini P, Marchesi F, Pastore D, Alessandrino EP, Annaloro C, Ciceri F, Santarone S, Nassi L, Farina C, Viscoli C, Rossolini GM, Bonifazi F, Rambaldi A; Gruppo Italiano Trapianto di Midollo Osseo (GITMO) and Associazione Microbiologi Clinici Italiani (AM-

CL1). Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. *Clin Infect Dis*. 2017 Nov 13;65(11):1884-1896.

10. Ricciardi MR, Mirabilii S, Licchetta R, Piedimonte M, Tafuri A. Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia. *Adv Biol Regul*. 2017 Aug;65:36-58
11. Annibaldi O, Tendas A, Pignatelli A, Mauroni R, Carli I, Chierichini A, Tomarchio V, Cupelli L, Saltarelli D, Inzeo A, Surano M, Piedimonte M, Marchesi F, Sollazzo F, Conte E, Viggiani C, Di Piazza F, Tirindelli MC, Arcese W; Quality of Life Working Party of the Rome Transplant Network. Protection during haemopoietic stem cell transplantation: a survey from the quality of life working party of the Rome Transplant Network. *BMJ Support Palliat Care*. 2017 Apr 3.
12. Tendas A, Cupelli L, Mauroni MR, Sollazzo F, Di Piazza F, Saltarelli D, Carli I, Chierichini A, Melfa C, Surano MA, Annibaldi O, Piedimonte M, Conte E, Marchesi F, Viggiani C, Pignatelli AC, Dentamaro T, de Fabritiis P, Perrotti AP, Arcese W; Quality of Life Working Party of the Rome Transplant Network. Patient-reported outcomes and quality of life assessment: New targets for new targeted therapy? *Cancer*. 2016 May 1;122(9):1461-2.
13. Girmenia C, Annino L, Mariotti B, Fanci R, Minotti C, Spadea A, Carotti A, Piedimonte M, Chierichini A, Cerchiara E, Caselli D, Cupelli L, Arcioni F, Bertaina A, Ribersani M, Proia A, Mengarelli A, Perriello V, Torelli GF, Di Gioia M, Del Principe MI, Cassetta MI, Fallani S, Novelli A. Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration? *Med Mycol*. 2016 Jul 1;54(5):445-58.
14. Tendas A, Cupelli L, Mauroni MR, Sollazzo F, Di Piazza F, Saltarelli D, Carli I, Chierichini A, Melfa C, Surano M, Annibaldi O, Piedimonte M, Conte E, Marchesi F, Viggiani C, Pignatelli AC, Dentamaro T, Niscola P, de Fabritiis P, Perrotti AP, Arcese W. Rehabilitation need and referrals in hematopoietic stem cell transplantation: the experience of Quality of Life Working Party of the Rome Transplant Network. *Bone Marrow Transplant*. 2016 May;51(5):638-9.
15. Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D, Sica S, Severino A, Cudillo L, Ciceri F, Scimè R, Lombardini L, Viscoli C, Rambaldi A; Gruppo Italiano Trapianto Midollo Osseo (GITMO); Gruppo Italiano Trapianto Midollo Osseo GITMO. Infections by carbapenem-resistant *Klebsiella pneumoniae* in SCT recipients: a nationwide retrospective survey from Italy. *Bone Marrow Transplant*. 2015 Feb;50(2):282-8.
16. Noris P, Klersy C, Gresele P, Giona F, Giordano P, Minuz P, Loffredo G, Pecci A, Melazzini F, Civaschi E, Mezzasoma A, Piedimonte M, Semeraro F, Veneri D, Menna F, Ciardelli L, Balduini CL; Italian Gruppo di Studio delle Piastrine. Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study. *Br J Haematol*. 2013 Jul;162(1):112-9.

Abstracts

1. Cox MC, Battistini R, Pelliccia S, Arcari A, Anticoli Borza P, Casaroli I, Zoli V, Di Landro F, Fabbri F, Galassi G, Leporace A, Piedimonte M, Di Girolamo M, Prosperi D, Campagna A, Di Napoli A, Tafuri A, Bocci G, Musuraca G. DEVEC metronomic schedule for aggressive B and T-cell lymphomas. June 4, 2018. Poster ASCO 2018. Abstract 7563.
2. Tendas A, Marchesi F, Annibaldi O, Becilli M, Chierichini A, Piccioni AL, Carli I, Saltarelli D, Sollazzo F, Molinari V, Piedimonte M, Melfa C, Cupelli L, Bruno A, Mauroni MR, Pignatelli AC, Viggiani C, De Angelis G, Tirindelli MC, Dentamaro T, De Fabritiis P, Niscola P, Perrotti AP, Arcese W. Rome Transplant Network Quality of Life. Quality of life during early phase of hemopoietic stem cell transplantation. Oct 15-18, 46th Congress of the Italian Society of Hematology. *Haematologica*, vol: 102, supplement: 3, pages: 32-32. Meeting Abstract: C060.
3. Tendas A, Marchesi F, Annibaldi O, Becilli M, Chierichini A, Piccioni AL, Carli I, Saltarelli D, Sollazzo F, Molinari V, Piedimonte M, Melfa C, Cupelli L, Bruno A, Mauroni MR, Pignatelli AC, Viggiani C, De Angelis G, Tirindelli MC, Dentamaro T, De Fabritiis P, Niscola P, Perrotti AP, Arcese W. Rome Transplant Network Quality of Life. Promotion of quality of life evaluation during early phase of hemopoietic stem cell transplantation: the experience of the Rome Transplant Network. Oct 15-18, 2017. 46th Congress of the Italian Society of Hematology. *Haematologica*, vol: 102, supplement: 3, pages: 152-152. Meeting abstract: p252.
4. Piedimonte M, Ferrari A, Conte E, Pelliccia S, Campagna A, Galassi G, Leporace A, Di Landro F, Bruno P, Santino I, De Carolis E, Torelli R, Terzo F, Mariotta S, Tafuri A. Diagnosis of invasive aspergillosis in hematological malignancies: the value of galactomannan test performed in both bronchoaspirate and peripheral blood. Oct 15-18, 2017. 46th SIE. *Haematologica*, vol: 102, supplement: 3, pages: 67-67. Meeting abstract: p042. Poster.

5. Leporace A, Campagna A, Piedimonte M, Pelliccia S, Galassi G, Di Landro F, Ferrari A, Conte E, Ricciardi MR, Mirabilli S, Licchetta R, Tafuri A. Adult T-cell leukemia: novel challenge for italian hematologists. Oct 15-18, 2017. 46th SIE. Rome, oct 15-18, 2017. *Haematologica*, vol: 102, supplement: 3, pages: 164-165. Meeting abstract: pu031.
6. Ferrari A, Pelliccia s, Leporace A, Galassi G, Piedimonte M, Campagna A, Di Landro F, Spiriti MAA, Cavalieri E, Conte E. Decitabine treatment for acute myeloid leukemia in elderly non-fit patients: a single institution experience. Oct 15-18, 2017. 46th SIE. *Haematologica*, vol: 102, supplement: 3, pages: 161-161. Meeting abstract: pu020.
7. Mirabilli S, Ricciardi MR, Licchetta R, Bianchi MP, Piedimonte M, Tafuri A. Targeting glycolysis and mapk pathway: a combined pre-clinical approach on acute myeloid leukemia. Dec 03-06, 2016. 58th AHS. *Blood*, vol: 128, issue: 22. Meeting abstract: 2751.
8. Tendas A, Cupelli L, Mauroni MR, Di Piazza F, Saltarelli D, Carli I, Chierichini A, Melfa C, Surano MA, Annibali O, Sollazzo F, Piedimonte M, Conte E, Marchesi F, Viggiani C, Pignatelli A, Dentamaro T, Perrotti AP, de Fabritiis P, Arcese W. Rome Transplant Network Quality of Life. Knowledge of nurses and physicians about chemotherapy induced nausea and vomiting (CINV) in the setting of hematopoietic stem cell transplantation (HSCT): the Rome Transplant Network (RTN) Experience. Apr 03-06, 2016. 42nd annual meeting of the EBMT. *EBMT*, vol: 51, supplement: 1, pages: s545-s545. Meeting abstract: np059
9. Giona F, Teofili L, Cecinati V, Palumbo G, Moleti ML, Rea M, Testi AM, Orlando SM, Piedimonte M, Nunes V, Capodimonte S, Nanni M, Larocca LM, Foa R. Thrombocythaemia in childhood: clinical and biological features, therapeutic approach and follow-up of 50 patients. Jun 06-08, 2010. 36th national congress of the Associazione Italiana Ematologia Oncologia Pediatrica. *Haematologica*, vol: 95, issue: 7, supplement: 1, pages: s66-s66.
10. Saltarelli F, Ferrari A, Bianchi MP, Piedimonte M, Naso V, Porrini R, Veggia B, Conte E, Cox MC, Montefusco E Fotemustine based platform conditioning regimen in relapsed non Hodgkin lymphoma patients eligible for autologous stem cell trasplant. *Haematologica*, ISSN: 0390-6078.
11. Conte E, Bianchi MP, Piedimonte M, Saltarelli F, Palmieri R, Montefusco E, Manfredi A, Lupo MT, Sollazzo F, Grigore D, Tudorache M, Ferrari A. New Peripherally Inserted Central Catheter (PICC) PowerGroshong device for haematological patients management: a single centre experience. *Atti della SIE*, issn: 0390-7910

Rome, 10/04/2021

In compliance with the UE 679/2016 regulation, I hereby authorize you to use and process my personal details contained in this document.